Monoclonal antibodies to hepatocyte growth factor

Details Monoclonal antibodies to hepatocyte growth factor Monoclonal antibodies to hepatocyte growth factor

2007-02-23

2009-02-24

Li, Ruixiang (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S141100, C530S388100, C530S388150

Reexamination Certificate

active

07494650

ABSTRACT:
The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

REFERENCES:
patent: 5004805 (1991-04-01), Gohda et al.
patent: 5646036 (1997-07-01), Schwall et al.
patent: 5686292 (1997-11-01), Schwall et al.
patent: 5707624 (1998-01-01), Nickoloff et al.
patent: 5997868 (1999-12-01), Goldberg et al.
patent: 6099841 (2000-08-01), Hillan et al.
patent: 6207152 (2001-03-01), Schwall et al.
patent: 6214344 (2001-04-01), Schwall et al.
patent: 6432406 (2002-08-01), Goldberg et al.
patent: 6468529 (2002-10-01), Schwall et al.
patent: 7220410 (2007-05-01), Kim et al.
patent: 2004/0110685 (2004-06-01), Brandt et al.
patent: 2004/0208876 (2004-10-01), Kim
patent: 2007/0036797 (2007-02-01), Kim
patent: 2007/0160613 (2007-07-01), Kim
patent: WO91/16928 (1991-11-01), None
patent: WO 01/34650 (2001-05-01), None
patent: WO 03/057155 (2003-07-01), None
patent: WO 2005/001486 (2005-01-01), None
patent: WO 2005/007193 (2005-01-01), None
patent: WO 2005/017107 (2005-02-01), None
patent: WO 2005/044848 (2005-05-01), None
patent: WO 2005/107800 (2005-11-01), None
patent: WO 2006/130773 (2006-12-01), None
U.S. Appl. No. 60/788,243, filed Apr. 1, 2006, Kim.
U.S. Appl. No. 60/751,092, filed Dec. 15, 2005, Kim.
U.S. Appl. No. 60/687,118, filed Jun. 2, 2005, Kim.
U.S. Appl. No. 60/464,061, filed Apr. 18, 2003, Kim.
U.S. Appl. No. 11/818,305, filed Jun. 13, 2007, Kim et al.
U.S. Appl. No. 11/731,774, filed Mar. 29, 2007, Kim.
Abounader et al., “Reversion of Human Glioblastoma Malignancy by U1 Small Nuclear RNA/Ribozyme Targeting of Scatter Factor/Hepatocyte Growth Factor and c-met Expression,”J Natl Cancer Inst, 91:1548-1556 (1999).
Advisory Action mailed Dec. 19, 2006 for U.S. Appl. No. 10/917,915.
Advisory Action mailed Oct. 30, 2006 for U.S. Appl. No. 10/917,915.
Anti-Human Hepatocyte Growth Factor (HGF) Developed in Goat, Affinity Isolated Antibody, product No. H7157, brochure for Sigma®.
Birchmeier et al., “Met, Metastasis, Motility and More,”Nature Reviews, 4:915-925 (2003).
Brockmann et al., “Inhibition of Intracerebral Glioblastoma Growth by Local Treatment with the Scatter Factor/Hepatocyte Growth Factor-Antagonist NK4,”Clinical Cancer Research, 9:4578-4585 (2003).
Burgess et al., “Fully Human Monoclonal Antibodies to Hepatocyte Growth Facto with Therapeutic Potential against Hepocyte Growth Factor/c-Met-Dependent human Tumors,”Cancer Res., 66(3):1721-1729 (2006).
Burr et al., “Anti-Hepatocyte Growth Factor Antibody Inhibits Hepatocyte Proliferation During Liver Regeneration,”Journal of Pathology, 185:298-302 (1998).
Cao et al., “Neutralizing monoclonal antibodies to hepatocyte growth factor / scatter factor HGF / SF) display antitumor activity in animal models,”PNAS, 98(13):7443-7448 (2001).
Danilkovitch-Miagkova et al., “Dysregulation of Met receptor tyrosine kinase activity in invasive tumors,”J. Clinical Investigation, 109(7):863-867 (2002).
Date et al., “Inhibition of tumor growth and invasion by a four kringle antagonist HGF / NK4) for hepatocyte growth factor,”Oncogene, 17:3045-3054 (1998).
Davies et al., “The HGF/SF Antagonist NK4 Reversed Fibroblast- and HGF-Induced prostate Tumor Growth and Angiogenesis in Vivo,”Int. J. Cancer, 106:348-354 (2003).
Di Nicola et al., “Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli,”Blood, 99(10):3838-3843 (2002).
Examiner Interview Summary mailed Oct. 26, 2006 for U.S. Appl. No. 10/917,915.
Hayashi et al., “Autocrine-Paracrine Effects of Overexpression of Heptocyte Growth Factor Gene on Growth of Endothelial Cells,”Biochem Biophys. Res. Comm., 220:539-545 (1996).
International Preliminary Report on Patentability with Written Opinion for PCT/US04/26565 mailed Jan. 7, 2005.
International Search Report for PCT/US04/26565 mailed Jan. 7, 2005.
Kermorgant et al., “Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase involvement,”Carcinogenesis, 22(7):1035-1042 (2001).
Kim et al., “Systemic Anti-Hepatocyte Growth Factor Monoclonal Antibody Therapy Induces the Regression of Intracranial Glioma Xenografts,”Clin. Cancer Res., 12(4):1292-1298 (2006).
Koochekpour et al., “Met and Hepatocyte Growth Factor/Scatter Factor Expression in Human Gliomas(1),”Cancer Research, 57:5391-5398 (1997).
Kuba et al., “HGF/NK4, a Four-Kringle Antagonist of Hepatocyte Growth Factor, Is an Angiogenesis Inhibitor that Suppresses Tumor Growth and Metastasis in Mice,”Cancer Research, 60:6737-6743 (2000).
Maulik et al., “Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition,”Cytokine&Growth Factor Reviews, 13:41-59 (2002).
Michieli et al., “Targeting the tumor and its microenvironment by a dual-function decoy Met receptor,”Cancer Cell, 6:61-73 (2004).
Monoclonal Anti-human HGF Antibody, brochure dated Jun. 3, 2002 by R & D Systems downloaded from WWW.rndsystems.com/pdf/MAF284.pdf.
Nishimura et al., “Prostate Stromal Cell-Derived Hepatocyte Growth Factor Induces Invasion of Prostate Cancer Cell Line DUI 45 Through Tumor-Stromal Interaction,”Prostate, 41:145-153 (1999).
Office Action mailed Jan. 10, 2006 for U.S. Appl. No. 10/917,915.
Office Action mailed Mar. 14, 2006 for U.S. Appl. No. 10/917,915.
Office Action mailed Aug. 11, 2006 for U.S. Appl. No. 10/917,915.
Prat et al., “Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF,”Journal of Cell Science, 111:237-247 (1998).
Principal Investigator: Jin K. Kim, Abstract of Grant No. 2R44CA101283-02, “Novel Monoclonal Antibody Therapy for Cancer,” pp. 1-2 from CRISP database, publishedca. Aug. 2005.
Principal Investigator: Jin K. Kim, Abstract of Grant No. 1R43CA101283-01A1, “Novel Monoclonal Antibody Therapy for Cancer,” pp. 1-2 from CRISP database, publishedca. Apr. 2004.
Principal Investigator: John L. Lattera, Abstract of Grant No. 2R01NS032148-04, “Biochemistry of Brain Tumor Microvessel Development,” pp. 1-2 printed from CRISP, publishedca. (1998).
Response dated Jan. 18, 2007 to Final Office Action mailed Aug. 11, 2006 for U.S. Appl. No. 10/917,915.
Response dated Nov. 15, 2006 to Final Office Action mailed Aug. 11, 2006 for U.S. Appl. No. 10/917,915.
Response dated Apr. 14, 2006 to Office Action mailed Mar. 14, 2006 for U.S. Appl. No. 10/917,915.
Response dated Jan. 27, 2006 to Restriction Requirement mailed Jan. 10, 2006 for U.S. Appl. No. 10/917,915.
Response Draft for Discussion with Examiner Only submitted Oct. 16, 2006 to Final Office Action mailed Aug. 11, 2006 for U.S. Appl. No. 10/917,915.
Schwall et al., “Inhibition of cmet activation by a one-armed antibody,”Proceedings of AACR, #1424 from vol. 45 (2004).
Supplemental Amendment dated Apr. 25, 2006 for U.S. Appl. No. 10/917,915.
Supplementary Partial European Search Report for European Application No. 04781281 dated Mar. 6, 2007.
Zaccolo et al., “Dimerization of Fab fragments enables ready screening of phage antibodies that affect hepatocyte growth factor/scatter factor activity on target cells,”Eur. J. Immunol., 27:618-623 (1997).

Affiliated with

Also associated with

Rating

Monoclonal antibodies to hepatocyte growth factor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Monoclonal antibodies to hepatocyte growth factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies to hepatocyte growth factor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4060344